Back to all studies
TerminatedNCT02237677

CB1 Receptor PET Imaging Reveals Gender Differences in PTSD

This study has public registry information. It focuses on PTSD and currently lists study information in the United States.

PTSD, PTSD (PTSD)ObservationalFrom 18 Years to 55 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT02237677. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

Check the official registry

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 1 site
  • NYU School of Medicine
    New York, New York
    Site status: Not listed — confirm with the team
In plain English

Key information made simple

What is this study testing?

This observational study follows adults living with ptsd to understand their experience, outcomes, or changes over time.

What would participation involve?

Participants may complete imaging scans, attend study visits with the research team. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with ptsd.

What should you check before joining?

Ask about whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateJune 2012
Recruitment status
Terminated
Enrollment listed in the registry
36
Sponsor
NYU Langone Health
Sponsor type
Unknown or unclear
Study type
Observational
Intervention type
OTHER
Study phase
Not clearly listed
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT02237677
Official title
Cannabinoid-1 (CB1) Receptor Positron Emission Tomography (PET) Imaging Reveals Gender Differences in Posttraumatic Stress Disorder (PTSD)
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT02237677. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

Based on the public registry summary, this study is trying to understand: The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including endocannabinoid (eCB) and glucocorticoids in the modulation of fear memories by examining the cannabinoid type 1 (CB1). The study team can confirm the exact objective and what it means for you.

Is this an interview, survey, or observational study?

This appears to be a interview / survey / observational study involving Positron emission tomography (PET) imaging. Phase is mainly useful to check for medication studies and some device studies.

Who might this study be for?

This study may concern people with ptsd; age range: From 18 Years to 55 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to answer questionnaires or take part in interviews. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

Could the questions feel emotionally difficult or personal?

If the study involves interviews or questionnaires, some questions may feel personal or emotionally sensitive. Ask whether you can skip questions, pause, stop, and how your answers will be protected. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by NYU Langone Health, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me